Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Achilles Therapeutics Plc (ACHL)

Achilles Therapeutics Plc (ACHL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 34,432
  • Shares Outstanding, K 41,088
  • Annual Sales, $ 0 K
  • Annual Income, $ -69,670 K
  • 60-Month Beta 1.32
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.25
Trade ACHL with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.60
  • Most Recent Earnings $-0.30 on 05/08/24
  • Next Earnings Date 08/02/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.41
  • Number of Estimates 2
  • High Estimate -0.33
  • Low Estimate -0.49
  • Prior Year -0.42
  • Growth Rate Est. (year over year) +2.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7940 +4.40%
on 06/28/24
0.9094 -8.85%
on 07/12/24
-0.0141 (-1.67%)
since 06/26/24
3-Month
0.7455 +11.19%
on 04/30/24
0.9703 -14.57%
on 05/10/24
+0.0689 (+9.07%)
since 04/26/24
52-Week
0.7400 +12.01%
on 04/26/24
1.7600 -52.90%
on 02/29/24
-0.1911 (-18.74%)
since 07/26/23

Most Recent Stories

More News
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation

NetworkNewsWire Editorial Coverage : More than 30 million people in the United States suffer with a rare disease; most of them are receiving no current treatment. Supporting the development and evaluation...

GNPX : 1.8600 (-3.63%)
RHHBY : 40.7600 (+3.03%)
JAZZ : 111.57 (+1.85%)
ALXO : 6.05 (-0.82%)
ACHL : 0.8289 (-1.09%)
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation

NetworkNewsWire Editorial Coverage : More than 30 million people in the United States suffer with a rare disease; most of them are receiving no current treatment. Supporting the development and evaluation...

GNPX : 1.8600 (-3.63%)
RHHBY : 40.7600 (+3.03%)
JAZZ : 111.57 (+1.85%)
ALXO : 6.05 (-0.82%)
ACHL : 0.8289 (-1.09%)
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation

EQNX::TICKER_START (NASDAQ:GNPX),(OTCQX:RHHBY),(NASDAQ:JAZZ),(NASDAQ:ALXO),(NASDAQ:ACHL) EQNX::TICKER_END

GNPX : 1.8600 (-3.63%)
RHHBY : 40.7600 (+3.03%)
JAZZ : 111.57 (+1.85%)
ALXO : 6.05 (-0.82%)
ACHL : 0.8289 (-1.09%)
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation

/PRNewswire/ -- More than 30 million people in the United States suffer with a rare disease; most of them are receiving no current treatment. Supporting the...

RHHBY : 40.7600 (+3.03%)
GNPX : 1.8600 (-3.63%)
JAZZ : 111.57 (+1.85%)
ALXO : 6.05 (-0.82%)
ACHL : 0.8289 (-1.09%)
Achilles Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights

- Additional clinical data from the ongoing Phase I/IIa trials in advanced NSCLC (CHIRON) and melanoma (THETIS) expected to be available in Q4 2022 - -...

ACHL : 0.8289 (-1.09%)
Achilles Therapeutics to lead Horizon Europe-Funded Consortium to Advance Personalized Cell Therapy Manufacturing

€4 million ($4.2 million) research and innovation award for consortium to develop first-in-class smart bioprocessing manufacturing platform...

ACHL : 0.8289 (-1.09%)
Achilles Therapeutics Appoints James Taylor as Chief Business Officer and Cassian Yee, MD to Scientific Advisory Board

LONDON, June 30, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T...

ACHL : 0.8289 (-1.09%)
Achilles Therapeutics Recognized with the 2022 PING Innovation Award

LONDON, June 21, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T...

ACHL : 0.8289 (-1.09%)
Achilles Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights

- Dosed first patient with higher-dose (Process 2) cNeT for advanced NSCLC (CHIRON) and initiated enrollment of cNeT + PD-1 inhibitor combination (THETIS...

ACHL : 0.8289 (-1.09%)
Achilles Therapeutics Doses First Patient with Higher-dose cNeT in Phase I/IIa CHIRON Trial in Advanced NSCLC and Initiates Enrollment in Cohort B of the THETIS Trial (cNeT + PD-1 checkpoint inhibitor) in Metastatic Malignant Melanoma

- THETIS Cohort B enrollment follows positive Independent Data Safety Monitoring Committee review - - Monotherapy data from higher-dose cohorts in both...

ACHL : 0.8289 (-1.09%)

Business Summary

Achilles Therapeutics plc is a clinical-stage biopharmaceutical company. It engages in developing precision T cell therapies to treat solid tumors. Achilles Therapeutics plc is based in LONDON.

See More

Key Turning Points

3rd Resistance Point 0.8693
2nd Resistance Point 0.8497
1st Resistance Point 0.8393
Last Price 0.8289
1st Support Level 0.8093
2nd Support Level 0.7897
3rd Support Level 0.7793

See More

52-Week High 1.7600
Fibonacci 61.8% 1.3704
Fibonacci 50% 1.2500
Fibonacci 38.2% 1.1296
Last Price 0.8289
52-Week Low 0.7400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar